Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.1

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Izrael - angol - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Izrael - angol - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Izrael - angol - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Izrael - angol - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Izrael - angol - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Izrael - angol - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard 7.5 mg is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer combination with radiotherapy.